Ten-year experience with primary ocular ‘reticulum cell sarcoma’ (large cell non-Hodgkin’s lymphoma)*

MARC J SIEGEL,† JACK DALTON,‡ ALAN H FRIEDMAN,† JAMES STRAUCHEN,§ † AND CAROLYN WATSON†

From the Departments of †Ophthalmology, ‡Radiation Therapy,§ Pathology, and †Neoplastic Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA

SUMMARY Fourteen patients with intraocular ‘reticulum cell sarcoma’ (non-Hodgkin’s large cell lymphoma) ranging in age from 27 to 77 are presented. All patients had evidence of vitritis with 50% showing intraretinal and/or subretinal lesions and 21% having anterior uveitis. Five of the patients developed central nervous system lesions and subsequently died. Primary radiation therapy to the eyes and CNS appears to prevent spread of the disease and improve longevity. Chemotherapy improved survival in one patient with CNS spread of disease.

Reticulum cell sarcoma (RCS) is a rare non-Hodgkin’s large cell lymphoma which can masquerade as chronic uveitis. This disease occurs in two broad forms, with one variety primarily involving the systemic lymph nodes, visceral organs, and uveal tract and another primarily affecting the retina, vitreous, and central nervous system (CNS). In the Rappaport classification the disease was relabelled as a histiocytic lymphoma.† More recently surface marker studies‡ have shown these cells to be of lymphoid and not histiocytic origin.

Over 100 cases§ of ocular RCS have been described in the literature. Typically, the patients have been in their sixth or seventh decade when either a unilateral or bilateral painless decrease in visual acuity occurred. No sexual or racial predilection has been noted. Invariably, ocular findings include vitreous cells and debris (Fig. 1). The retina and choroid (Fig. 2), the conjunctiva, and the optic nerve may be infiltrated by tumour. Less commonly an anterior chamber reaction or an exudative retinal detachment may be presenting sign (Fig. 3). Systemic spread is common, with the CNS being affected first (Fig. 4). It is not clear if this spread of tumour represents true metastatic disease or whether it reflects a multicentric origin of the lymphoma. Diagnosis is achieved by means of vitreous aspiration and examination of a slide prepared from the cytopsin or Millipore filter of the specimen (Fig. 5).

Over the last 10 years we have had the opportunity to treat 14 patients with RCS, with a follow-up time of up to seven years. A profile of these patients, their clinical findings, and treatment is presented (Table 1).

*Presented at the annual meeting of the American Academy of Ophthalmology in Dallas, Texas on 11 November 1987.

Correspondence to Alan H Friedman, MD Department of Ophthalmology, Box 1183, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA

Fig. 1 Vitritis and subretinal lesions in patient with active disease.
Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma)

Results

The age at presentation ranged from 27 to 77 years, mean 65. Nine out of 14 or 64% of the patients were women, with no black patients in our series. Disease was bilateral in 71% of the patients. There was vitritis in 100% of the patients and retinal/subretinal lesions in 50%. Three of the fourteen patients had an anterior uveitis as well, with one being moderately intense.

Initial investigations included a complete systemic evaluation with head CT scan, lumbar puncture for examination of cerebrospinal fluid, and bone marrow aspiration. Central nervous system involvement was present at the time of initial diagnosis in two cases and subsequently developed in four additional patients. All patients with CNS lesions except one died about six months after the presence of these lesions was confirmed.

The diagnosis of RCS was confirmed in 11 patients by means of a vitreous aspiration. This was performed with a 19 gauge needle introduced via the pars plana with 0.5 ml of fluid aspirated. One patient refused any diagnostic or therapeutic manoeuvres and two patients were not suspected of harbouring RCS until the time of necropsy. Nine patients who were diagnosed by vitreous aspiration underwent radiation therapy. Of the two patients who received radiation only to the orbits and not the brain one subsequently developed CNS lesions. One patient who received CNS and orbital radiation had an ocular recurrence after one year and systemic recurrence 18 months after initial diagnosis (Fig. 4) but was without evidence of CNS spread. In an additional
patient an ocular recurrence and a new brain lesion appeared one and one-half years after ocular and CNS radiation.

In patients who received primary radiation therapy, chemotherapy was reserved for recurrent CNS disease and was effective in one case in causing regression of tumour and preventing death. Two patients received intravenous cytosine arabinoside (Ara-C) as primary therapy for localised ocular disease. At three months follow-up there was no evidence of metastatic disease and partial improvement in ocular findings, though visual acuity remained unchanged.

Our chemotherapy protocol was to give Ara-C 2000–3000 mg/m² intravenously over a period of one hour. Treatment was repeated every 12 hours for three doses in the hospital and then as single doses repeated at weekly intervals as an outpatient. Toxicity was minimal, consisting of nausea, vomiting, and myelosuppression. No patients showed signs of CNS or cerebellar toxicity.

Discussion

Our findings confirm many of those noted in smaller series of cases of RCS. Although the mean age of 65 in our series is similar to that in previous reports, one patient was 27 at initial diagnosis. Interestingly, the first patient described with RCS was also 27¹¹ and so emphasises that, though very unusual, this condition should be thought of in younger patients as well as the elderly.

The most frequent finding in this series was an unexplained posterior and occasionally anterior uveitis. While negative blood studies, chest x-ray, and a thorough retinal examination can help to exclude some causes of uveitis, a vitreous aspiration is required for definitive diagnosis. This procedure was performed in all of our patients who consented and in whom the diagnosis was suspected. When present, a characteristic funduscopic picture of multicentric subretinal pigment epithelial lesions¹²¹³ can help suggest the diagnosis of RCS and was present in half our cases.

Tissue typing is useful in systemic lymphomas both for prognosis and in guiding therapy. Determining whether our cases of RCS were of B-cell or T-cell origin was very difficult given the small volume of vitreous aspirate obtained in individual cases. Only one patient could be typed and this patient had a T-cell lymphoma. Other workers have noted a predominance of B-cell lymphomas,¹⁴ but all involve a small number of cases. Whether this information will become useful in future in planning treatment of RCS remains to be determined. It is possible that a pars plana vitrectomy would facilitate typing by providing

![High-power view of vitreous cytospin showing the large atypical cells seen in large cell lymphoma. Giemsa, ×1200.](image-url)
Table 1  Data summary of patients with reticulum cell sarcoma seen over the last 10 years

<table>
<thead>
<tr>
<th>Age/sex</th>
<th>Initial visual acuity</th>
<th>Ocular findings at presentation</th>
<th>CNS lesions at presentation</th>
<th>Radiation treatment</th>
<th>Chemotherapy</th>
<th>Recurrence</th>
<th>Outcome</th>
<th>Length of follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>55/F</td>
<td>20/20 20/25</td>
<td>Vitreous cells, OS</td>
<td>Yes</td>
<td>40 grey (4000 rad) brain and OS</td>
<td>Cytoxan, Adriamycin, prednisone, vincristine (used after recurrence)</td>
<td>CNS lesions</td>
<td>Died 1½ yr</td>
<td></td>
</tr>
<tr>
<td>60/F</td>
<td>20/30 20/25</td>
<td>Vitreous cells OU</td>
<td>None</td>
<td>40 grey brain and OU</td>
<td>None</td>
<td>None</td>
<td>Visual acuity unchanged, no metastases</td>
<td>6 mon</td>
</tr>
<tr>
<td>27/F</td>
<td>20/15 20/50</td>
<td>Vitreous cells, OU; focal area of RPE atrophy OS</td>
<td>None</td>
<td>40 grey brain and OU</td>
<td>IV Ara-C after recurrence</td>
<td>CNS after 1½ years</td>
<td>20/20 OU, metastases improved with Ara-C</td>
<td>18 mon</td>
</tr>
<tr>
<td>66/F</td>
<td>20/50 20/40</td>
<td>Vitreous cells and posterior vitreous detachment OU</td>
<td>None</td>
<td>40 grey brain and OU</td>
<td>None</td>
<td>None</td>
<td>20/30 OU</td>
<td>9 mon</td>
</tr>
<tr>
<td>55/F</td>
<td>20/70 20/20</td>
<td>Anterior uveitis OU; Koepe nodule OD; retinal masses/infiltrates OD; vitreous cells OU</td>
<td>None</td>
<td>4000 rad brain and OU</td>
<td>None</td>
<td>None</td>
<td>20/20 OU; required low dose oral prednisone for mild persistent uveitis. Repeat vitreous tap normal 1 year ago</td>
<td>3½ yr</td>
</tr>
<tr>
<td>70/M</td>
<td>20/200 20/200</td>
<td>Vitreous cells OU</td>
<td>None</td>
<td>40 grey OU</td>
<td>Methotrexate, Adriamycin, prednisone (used after recurrence)</td>
<td>CNS lesions in 6 months</td>
<td>Lost to follow-up, visual acuity 20/70 OD and 20/400 OS, CNS lesions still present and patient gravely ill</td>
<td>2 yr</td>
</tr>
<tr>
<td>64/F</td>
<td>20/70 20/200</td>
<td>Vitreous cells OU, cystoid macular oedema and retinal exudates OS</td>
<td>None</td>
<td>20 grey OU</td>
<td>None</td>
<td>None</td>
<td>20/20 OD, 20/70 OS, no metastases or large bowel involvement</td>
<td>7½ yr</td>
</tr>
<tr>
<td>70/M</td>
<td>20/70, Finger counting</td>
<td>Vitreous cells OU, retinal exudates OS</td>
<td>None</td>
<td>40 grey brain and OU</td>
<td>None</td>
<td>Ocular, and large bowel involvement, 1 year. No CNS lesion</td>
<td>20/80 OD, 20/100 OS, terminally ill</td>
<td>1½ yr</td>
</tr>
<tr>
<td>61/M*</td>
<td>20/30 20/30</td>
<td>Vitreous cells OU</td>
<td>None</td>
<td>Refused</td>
<td>Refused</td>
<td>None</td>
<td>Died 6 months with CNS disease</td>
<td>20/30 OD and 20/50 OS</td>
</tr>
<tr>
<td>68/M</td>
<td>20/30, Finger counting</td>
<td>Coarse vitritis OD, retinal exudates OS</td>
<td>None</td>
<td>40 grey brain and eyes</td>
<td>None</td>
<td>None</td>
<td>Diagnosed post mortem</td>
<td></td>
</tr>
<tr>
<td>66/M*</td>
<td>20/400 20/40</td>
<td>Trace anterior uveitis OU, subretinal lesions OS, vitreous cells OU</td>
<td>None</td>
<td>None</td>
<td>40 mg prednisone p.o. qD</td>
<td>Died after 6 mon</td>
<td>Diagnosed post mortem</td>
<td></td>
</tr>
<tr>
<td>77/F*</td>
<td>20/30 20/200</td>
<td>Vitreous cells OU, retinal exudates OS</td>
<td>None</td>
<td>None</td>
<td>40 mg prednisone orally as required</td>
<td>Died after 6 mon</td>
<td>Diagnosed post mortem</td>
<td></td>
</tr>
<tr>
<td>66/M</td>
<td>20/20 20/50</td>
<td>Trace anterior uveitis OS, 4+ vitreous cells OS</td>
<td>None</td>
<td>None</td>
<td>IV Ara-C</td>
<td>None</td>
<td>Vision unchanged</td>
<td>3 mon</td>
</tr>
<tr>
<td>62/F</td>
<td>20/30 20/100</td>
<td>Trace anterior uveitis OS, 4+ vitreous cells OS</td>
<td>None</td>
<td>None</td>
<td>IV Ara-C</td>
<td>None</td>
<td>Vision unchanged</td>
<td>3 mon</td>
</tr>
</tbody>
</table>

*Cases previously reported.*

A larger quantity of cells than is obtained by vitreous aspiration.

The rapid demise of all patients who developed central nervous system lesions speaks for the need to prevent spread of this rapidly fatal disease. Radiation therapy causes effective amelioration of ocular symptoms and was usually given in a dosage of 40 grey (4000 rad). Although largely empirical, whole brain radiation of 40 grey was also given in the hope of preventing CNS spread of disease. Within the limitations of our follow-up only one patient who was free of CNS lesions at presentation and received prophylactic whole brain radiation subsequently developed CNS metastasis. One additional patient developed...
systemic but not CNS spread of disease. This contrasts with a 75% incidence of CNS involvement reported in other series. Our radiation protocol is similar to that used in other centres. 16

The use of chemotherapy for RCS is less clear. The experience of Char et al. 17 with three patients given combination chemotherapy, including intrathecal treatment, was favourable. Baumann et al. 18 successfully treated one patient with intravenous high-dose cytosine arabinoside (Ara-C) who suffered recurrence after radiation therapy. Evidence suggests that Ara-C reaches therapeutic levels in the CSF and vitreous after intravenous therapy. 19 Our experience with three patients given high-dose intravenous Ara-C has been encouraging. Our one patient with the best response had received radiation therapy primarily. A prospective trial to evaluate the role of systemic high-dose Ara-C in combination with ocular and CNS irradiation as primary therapy needs to be undertaken.

In summary, a high degree of suspicion is needed in patients in whom a chronic posterior uveitis of obscure aetiology persists. Chronic uveitis is unusual in people over 60, and the differential diagnosis includes sarcoidosis, syphilis, tuberculosis, toxoplasmosis, Whipple’s disease, cytomegalovirus infection, metastatic disease, and amyloid disease. The presence of multifocal subretinal lesions is even more suggestive of RCS. If the diagnosis of RCS is entertained, diagnosis can easily be confirmed by means of a vitreous aspiration. It should be remembered that young patients may occasionally be affected with this disease as well. It seems reasonable that such patients with idiopathic posterior uveitis with or without characteristic fundus lesions should undergo diagnostic vitreous aspiration.

We thank Ms Elizabeth Wilkins and Ms DonnaMarie Petrino for assistance in typing the manuscript.

This work was supported in part by an unrestricted grant from Research to Prevent Blindness, New York, NY.

References


Ten-year experience with primary ocular 'reticulum cell sarcoma' (large cell non-Hodgkin's lymphoma).

M J Siegel, J Dalton, A H Friedman, J Strauchen and C Watson

doi: 10.1136/bjo.73.5.342

Updated information and services can be found at:
http://bjo.bmj.com/content/73/5/342

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/